These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Exponential growth status of the cell number. I. The independence of the portion of proliferating cells found in different phases of the mitotic cycle from the variability in phase durations]. Gushchin VA Tsitologiia; 1981 Dec; 23(12):1428-36. PubMed ID: 7330982 [TBL] [Abstract][Full Text] [Related]
3. Aggregation kinetics of well and poorly differentiated human prostate cancer cells. Enmon RM; O'Connor KC; Song H; Lacks DJ; Schwartz DK Biotechnol Bioeng; 2002 Dec; 80(5):580-8. PubMed ID: 12355469 [TBL] [Abstract][Full Text] [Related]
4. Inflammation, atrophy, and prostate carcinogenesis. De Marzo AM; Nakai Y; Nelson WG Urol Oncol; 2007; 25(5):398-400. PubMed ID: 17826659 [TBL] [Abstract][Full Text] [Related]
5. [Mathematical modelling of the kinetics of a heterogeneous cell population during tumor growth. I. Analytical study]. Bardychev DM; Ivanov VK Tsitologiia; 1984 Dec; 26(12):1357-64. PubMed ID: 6528359 [TBL] [Abstract][Full Text] [Related]
6. Prostatic carcinoma: a trilogy of clinical expressions. Johnson DE; von Eschenbach AC South Med J; 1980 Oct; 73(10):1304-7. PubMed ID: 7434040 [TBL] [Abstract][Full Text] [Related]
7. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Gao J; Arnold JT; Isaacs JT Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338 [TBL] [Abstract][Full Text] [Related]
8. [Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]. Pozharisskiĭ KM; Leenman EE; Arzumanov AA Arkh Patol; 2005; 67(5):15-9. PubMed ID: 16323473 [TBL] [Abstract][Full Text] [Related]
9. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma. Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195 [TBL] [Abstract][Full Text] [Related]
10. [Research at the Ulm University in prostate cancer]. Rinnab L; Cronauer M; Spindler D; Hautmann RE; Küfer R Urologe A; 2007 Sep; 46(9):1071-7. PubMed ID: 17628778 [No Abstract] [Full Text] [Related]
11. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Hayward SW; Wang Y; Cao M; Hom YK; Zhang B; Grossfeld GD; Sudilovsky D; Cunha GR Cancer Res; 2001 Nov; 61(22):8135-42. PubMed ID: 11719442 [TBL] [Abstract][Full Text] [Related]
13. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Olapade-Olaopa EO; MacKay EH; Taub NA; Sandhu DP; Terry TR; Habib FK Clin Cancer Res; 1999 Mar; 5(3):569-76. PubMed ID: 10100708 [TBL] [Abstract][Full Text] [Related]
14. Diverse ideas on the growth kinetics of disseminated cancer cells. Afenya EK; Calderón CP Bull Math Biol; 2000 May; 62(3):527-42. PubMed ID: 10812720 [TBL] [Abstract][Full Text] [Related]
15. Regulation of the expression of prostatic acid phosphatase in LNCaP human prostate carcinoma cells. Lin MF; Garcia-Arenas R; Kawachi M; Lin FF Cell Mol Biol Res; 1993; 39(8):739-50. PubMed ID: 7951413 [TBL] [Abstract][Full Text] [Related]
16. A bridge between neuroscience and oncology: prostate cancer genesis. A 'negative' consequence of learning? Zermann DH; Ishigooka M; Schmidt RA Med Hypotheses; 2001 Aug; 57(2):201-6. PubMed ID: 11461173 [TBL] [Abstract][Full Text] [Related]
17. Dynamics of prostate cancer stem cells with diffusion and organism response. Quinn T; Sinkala Z Biosystems; 2009 Apr; 96(1):69-79. PubMed ID: 19111893 [TBL] [Abstract][Full Text] [Related]
18. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report]. Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339 [TBL] [Abstract][Full Text] [Related]
19. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II. Song K; Cornelius SC; Danielpour D Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605 [TBL] [Abstract][Full Text] [Related]
20. Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. Boffa LC; Scarfi S; Mariani MR; Damonte G; Allfrey VG; Benatti U; Morris PL Cancer Res; 2000 Apr; 60(8):2258-62. PubMed ID: 10786693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]